Since recurrent FSGS was postulated to be caused by CPF affecting podocyte structure and function, interventions such as PE and RTX may result in improved outcomes in treatment rather than prevention of recurrence [16]. The gene discussed is NR5A2; the disease is focal segmental glomerulosclerosis.